Skip to main content

Table 3 Clinical manifestations of Henoch–Schönlein purpura patients with increased fecal calprotectin levels

From: Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch–Schönlein purpura patients: a retrospective analysis

Variable Total HSP patients (n = 69) Fecal calprotectin > 50 mg/kg (n = 45) Fecal calprotectin < 50 mg/kg (n = 24) P value
Duration of admission (days) 5.41 ± 5.27 6.33 ± 5.88 3.61 ± 3.22 0.043*
Patients with gastrointestinal symptoms 40 (58.0%) 35 (77.8%) 5 (20.8%) 0.000*
 Upper gastrointestinal tract involvement 22/40 (55.0%) 19/35 (54.3%) 3/5 (60.0%) 1.000
 Lower gastrointestinal tract involvement 18/40 (45.0%) 16/35 (45.7%) 2/5 (40.0%)
Duration of gastrointestinal symptoms (days) 2.88 ± 4.02 3.89 ± 4.35 1.00 ± 2.41 0.001*
HSP clinical score 1.99 ± 1.53 2.36 ± 1.61 1.29 ± 1.08 0.005*
Gastrointestinal involvement score 0.93 ± 0.93 1.27 ± 0.89 0.29 ± 0.62 0.000*
HSP recurrence 23 (33.3%) 18 (40.0%) 5 (20.8%) 0.108
Gastrointestinal symptom recurrence 19 (27.5%) 15 (33.3%) 4 (16.7%) 0.167
Positive stool occult blood result 17 (24.6%) 16 (35.6%) 1 (4.2%) 0.003*
  1. HSP Henoch–Schönlein purpura
  2. *Significant findings at P < 0.05